CovidChloroV1, Main, Corpus, bibRecord, 001650

Should coronavirus disease 2019 concern rheumatologists?

Identifieur interne : 001650 ( Main/Corpus ); précédent : 001649; suivant : 001651

Should coronavirus disease 2019 concern rheumatologists?

Auteurs : Eugeniusz J. Kucharz

Source :

Polish archives of internal medicine [ 1897-9483 ] ; 2020.

RBID : pubmed:32426957

English descriptors

KwdEn :
- Antirheumatic Agents (therapeutic use), COVID-19 (MeSH), Chloroquine (therapeutic use), Coronavirus Infections (drug therapy), Humans (MeSH), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Rheumatic Diseases (drug therapy), Rheumatologists (standards).
MESH :
- chemical , therapeutic use : Antirheumatic Agents, Chloroquine, Hydroxychloroquine.
- drug therapy : Coronavirus Infections, Pneumonia, Viral, Rheumatic Diseases.
- standards : Rheumatologists.
- COVID-19, Humans, Pandemics.

Abstract

Coronavirus disease 2019 (COVID‑19) is an infectious disease that became a global health emergency. This review focuses on the aspects of COVID‑19 pertaining to rheumatology, including signs and symptoms akin to those observed in rheumatic disorders, risk of infection or severe course of the disease in patients with a pre‑ existing rheumatic disease and those receiving antirheumatic or immunosuppressive medication, as well as potential use of antirheumatic or anticytokine therapeutic strategies that are already applied in rheumatology (among others, chloroquine, hydroxychloroquine, tocilizumab, and baricitinib) in patients with COVID‑19.

DOI: 10.20452/pamw.15366
PubMed: 32426957

Links to Exploration step

pubmed:32426957

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Should coronavirus disease 2019 concern rheumatologists?</title>
<author><name sortKey="Kucharz, Eugeniusz J" sort="Kucharz, Eugeniusz J" uniqKey="Kucharz E" first="Eugeniusz J" last="Kucharz">Eugeniusz J. Kucharz</name>
<affiliation><nlm:affiliation>Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical University of Silesia, Katowice, Poland. ejkucharz@poczta.onet.pl</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32426957</idno>
<idno type="pmid">32426957</idno>
<idno type="doi">10.20452/pamw.15366</idno>
<idno type="wicri:Area/Main/Corpus">001650</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001650</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Should coronavirus disease 2019 concern rheumatologists?</title>
<author><name sortKey="Kucharz, Eugeniusz J" sort="Kucharz, Eugeniusz J" uniqKey="Kucharz E" first="Eugeniusz J" last="Kucharz">Eugeniusz J. Kucharz</name>
<affiliation><nlm:affiliation>Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical University of Silesia, Katowice, Poland. ejkucharz@poczta.onet.pl</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Polish archives of internal medicine</title>
<idno type="eISSN">1897-9483</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antirheumatic Agents (therapeutic use)</term>
<term>COVID-19 (MeSH)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Rheumatic Diseases (drug therapy)</term>
<term>Rheumatologists (standards)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
<term>Rheumatic Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Rheumatologists</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronavirus disease 2019 (COVID‑19) is an infectious disease that became a global health emergency. This review focuses on the aspects of COVID‑19 pertaining to rheumatology, including signs and symptoms akin to those observed in rheumatic disorders, risk of infection or severe course of the disease in patients with a pre‑ existing rheumatic disease and those receiving antirheumatic or immunosuppressive medication, as well as potential use of antirheumatic or anticytokine therapeutic strategies that are already applied in rheumatology (among others, chloroquine, hydroxychloroquine, tocilizumab, and baricitinib) in patients with COVID‑19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32426957</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1897-9483</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>130</Volume>
<Issue>7-8</Issue>
<PubDate><Year>2020</Year>
<Month>08</Month>
<Day>27</Day>
</PubDate>
</JournalIssue>
<Title>Polish archives of internal medicine</Title>
<ISOAbbreviation>Pol Arch Intern Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Should coronavirus disease 2019 concern rheumatologists?</ArticleTitle>
<Pagination><MedlinePgn>655-661</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.20452/pamw.15366</ELocationID>
<Abstract><AbstractText>Coronavirus disease 2019 (COVID‑19) is an infectious disease that became a global health emergency. This review focuses on the aspects of COVID‑19 pertaining to rheumatology, including signs and symptoms akin to those observed in rheumatic disorders, risk of infection or severe course of the disease in patients with a pre‑ existing rheumatic disease and those receiving antirheumatic or immunosuppressive medication, as well as potential use of antirheumatic or anticytokine therapeutic strategies that are already applied in rheumatology (among others, chloroquine, hydroxychloroquine, tocilizumab, and baricitinib) in patients with COVID‑19.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kucharz</LastName>
<ForeName>Eugeniusz J</ForeName>
<Initials>EJ</Initials>
<AffiliationInfo><Affiliation>Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical University of Silesia, Katowice, Poland. ejkucharz@poczta.onet.pl</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Poland</Country>
<MedlineTA>Pol Arch Intern Med</MedlineTA>
<NlmUniqueID>101700960</NlmUniqueID>
<ISSNLinking>0032-3772</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012216" MajorTopicYN="N">Rheumatic Diseases</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000072140" MajorTopicYN="N">Rheumatologists</DescriptorName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32426957</ArticleId>
<ArticleId IdType="doi">10.20452/pamw.15366</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001650 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001650 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32426957
   |texte=   Should coronavirus disease 2019 concern rheumatologists?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32426957" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Should coronavirus disease 2019 concern rheumatologists?

Should coronavirus disease 2019 concern rheumatologists?

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki